DOVER, DE -- March 20, 2017 -- InvestorsHub NewsWire -- Metatron
(OTC
PINK: MRNJ) announces its plan to release the new and
revamped Canniboids app during the annual cannabis traffic surge,
4/20 (April 20th, 2017). Cannaboids.com, an Organic Nutraceuticals
Portal, was designed for medical marijuana patients to have the
resources to find the latest CBD news and connect to legal
dispensaries. History has shown the weeks leading up to April 20th,
dispensaries around the country show a significant increase in
traffic and cannabis sales.
The Cannaboids app was created by Metatron's subsidiary,
i-Mobilize app division and was the pioneer to put any Hemp related
app on iTunes, and this was the first app to market CBD based
products exclusively. The app is based on Metatron's CDB portal and
brand, cannaboids.com.
Similar to WeedMaps, the #1 Medical Marijuana app with an
estimated $400k a month in sales according to Fast Company,
Metatron's app has provided users with access and reviews to
distributors of cannabinoid based products. The difference is the
company's app provides audio and video content and only feature
products legal in all 50 states and most countries.
In recent news, it is stated that legal marijuana sales are
projected to reach $20.6 billion by 2020, a significant increase
from its current $7.4 billion level.
CBD is an abbreviation for cannabidiol, a prominent
naturally-occurring cannabinoid compound that may have medical
benefits. CBD can be made from the mature stalks of the industrial
hemp plants and can be legally imported into the United States
under Federal Law. Scientific and clinical studies underscore CBD's
potential as a treatment for a wide range of conditions, including
arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia,
PTSD, antibiotic-resistant infections, epilepsy, and other
neurological disorders. CBD has demonstrated neuroprotective and
neurogenic effects, and its anti-cancer properties are currently
being investigated at several academic research centers in the
United States and elsewhere. It is important to note that CBD is
not approved for the diagnosis, cure, mitigation, treatment, or
prevention of any disease.
Mobile Rebranding
The Company, through its mobile division i-Mobilize, plans to
relaunch their mobile business in the specific areas of mobile
encryption and security, and mobile applications for the growing
cannabis and marijuana market. Under this new goal, the Company
will keep its focus on a couple of dynamic concepts within the
mobile market, and will look to reduce or shelve other projects to
the back burner, which may be a smart move as to keep them focused
on one or two projects at a time.
The Company has experience in developing over 2000+ mobile
applications in the past years with over 3.5 million in
sales.
Download Apps
People interested can view and download our current live apps
focused on mental health and wellness by visiting the app stores
below. We plan to update these apps in our upcoming relaunch, and
will be adding a couple more to our list. Stay tuned!
iTunes: https://itunes.apple.com/us/artist/i-mobilize-inc./id325075390
Google Play: https://play.google.com/store/apps/developer?id=Metatron+Inc
Facebook: http://www.facebook.com/metatroninc
Twitter: http://twitter.com/metatroninc
News: http://metatroninc.com/blog
Forward-Looking Statements: Any statements made in this press
release which are not historical facts contain certain
forward-looking statements, as such term is defined in the Private
Litigation Reform Act of 1995, concerning potential developments
affecting the business, prospects, financial condition and other
aspects of the company to which this release pertains. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results
of the specific items described in this release, and the company's
operations generally, to differ materially from what is projected
in such forward-looking statements. Although such statements are
based upon the best judgments of management of the company as of
the date of this release, significant deviations in magnitude,
timing and other factors may result from business risks and
uncertainties including, without limitation, the company's need for
additional financing, which is not assured and which may result in
dilution of shareholders, the company's status as a small company
with a limited operating history, dependence on third parties and
the continuing popularity of the iOS operating system, general
market and economic conditions, technical factors, receipt of
revenues, and other factors, many of which are beyond the control
of the company. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot
guarantee future results, levels of activity, performance, or
achievements. Moreover, neither we nor any other person assumes
responsibility for the accuracy and completeness of such
statements, and we disclaim any obligation to update information
contained in any forward looking statement. Metatron retained
Global Discovery Group Inc. for $30,500 for consulting services,
CSC Partners for $1,500, Bas1 for $2501and the company retained
Pacific Equity Alliance LLC by issuing Integrative Business
Alliance LLC 100m rule 144 for 1 year consulting services. Metatron
does not grow, sell or distribute any substances that violate
United States Law or the controlled substance act.
